|
BMS1P4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.20400000156596E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.27260000315488E-08 |
| Normal-vs-Stage2 |
1.88639999953999E-07 |
| Normal-vs-Stage3 |
1.46490000130228E-08 |
| Normal-vs-Stage4 |
3.56079998820036E-09 |
| Stage1-vs-Stage2 |
1.278420E-01 |
| Stage1-vs-Stage3 |
3.070200E-02 |
| Stage1-vs-Stage4 |
1.183740E-02 |
| Stage2-vs-Stage3 |
9.544400E-01 |
| Stage2-vs-Stage4 |
4.007800E-01 |
| Stage3-vs-Stage4 |
3.657000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.87930000012027E-07 |
| Normal-vs-AfricanAmerican |
3.496100E-03 |
| Normal-vs-Asian |
6.7762000011129E-08 |
| Caucasian-vs-AfricanAmerican |
6.137000E-01 |
| Caucasian-vs-Asian |
1.307400E-01 |
| AfricanAmerican-vs-Asian |
1.720590E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.4494999602901E-09 |
| Normal-vs-Female |
2.93880000001856E-07 |
| Male-vs-Female |
6.116300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.19339999996127E-06 |
| Normal-vs-Age(41-60Yrs) |
3.54810003599937E-09 |
| Normal-vs-Age(61-80Yrs) |
2.35279999927229E-08 |
| Normal-vs-Age(81-100Yrs) |
1.69921999999545E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.797600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.078200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.927800E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.576200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.150000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.877200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.766900E-04 |
| Classical-VS-Follicular |
2.834000E-01 |
| Classical-VS-Other |
3.710600E-01 |
| Classical-VS-Normal |
1.14719999999569E-06 |
| Tall-VS-Follicular |
8.282100E-02 |
| Tall-VS-Other |
6.452200E-01 |
| Tall-VS-Normal |
9.19979981084396E-10 |
| Follicular-VS-Other |
7.006000E-01 |
| Follicular-VS-Normal |
2.82709999965824E-07 |
| Other-VS-Normal |
9.077300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.71490000036678E-07 |
| Normal-vs-N1 |
3.61020000000378E-05 |
| N0-vs-N1 |
8.898800E-01 |
|
|
